Dr. Kudo on Cost-Effectiveness Analysis of Lenvatinib Versus Sorafenib

Video

Masatoshi Kudo, MD, PhD, professor and chairman, Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan, discusses the results of a cost-effectiveness analysis of lenvatinib versus sorafenib in unresectable hepatocellular carcinoma in Japan.

Masatoshi Kudo, MD, PhD, professor and chairman, Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan, discusses the results of a cost-effectiveness analysis of lenvatinib (Lenvima) versus sorafenib in unresectable hepatocellular carcinoma (HCC) in Japan.

Using data from the phase III REFLECT clinical trial, Kudo and colleagues developed a partitioned survival model to estimate the cost to treat Japanese patients with HCC over a lifetime horizon, taking into consideration indirect costs, such as hospital admissions, to the Japanese healthcare system. Data showed that lenvatinib confers a greater benefit in terms of quality-adjusted life years (QALYs)—at a lower cost—than does sorafenib.

It is a rare scenario in which a new drug provides greater benefit in QALYs with a lower cost than the standard of care, and the results of the analysis suggest that lenvatinib can provide a benefit not only to patients, but also to the healthcare system as a whole, Kudo concludes.

View more from the 2018 International Liver Cancer Association Annual Conference

Brought to you in part by Eisai

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center